BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements
This article was originally published in The Gray Sheet
Executive Summary
BioMérieux announced two deals last week as part of its five-year strategic plan focusing on infectious diseases and personalized diagnostics
You may also be interested in...
bioMérieux HPV test
Paris firm launches human papillomavirus (HPV) diagnostic in Europe April 23. The test, which uses NorChip's m-RNA-based Pre-Tect HPV-proofer on bioMérieux's NucliSENS EasyQ platform, is the result of a recently signed license agreement intended to expand the latter firm's footprint in the infectious disease diagnostic market (1"The Gray Sheet" Jan. 22, 2007, p. 21). bioMérieux's molecular diagnostic enables assessment of the virus' oncogenicity, a feature unattainable with viral DNA tests, the firm says. Digene's DNAwithPap is the only FDA-approved test for HPV, the primary cause of cervical cancer. Roche (Amplicor), Gen-Probe (Aptima), Ventana (Inform) and Third Wave Technologies are developing HPV tests...
bioMérieux HPV test
Paris firm launches human papillomavirus (HPV) diagnostic in Europe April 23. The test, which uses NorChip's m-RNA-based Pre-Tect HPV-proofer on bioMérieux's NucliSENS EasyQ platform, is the result of a recently signed license agreement intended to expand the latter firm's footprint in the infectious disease diagnostic market (1"The Gray Sheet" Jan. 22, 2007, p. 21). bioMérieux's molecular diagnostic enables assessment of the virus' oncogenicity, a feature unattainable with viral DNA tests, the firm says. Digene's DNAwithPap is the only FDA-approved test for HPV, the primary cause of cervical cancer. Roche (Amplicor), Gen-Probe (Aptima), Ventana (Inform) and Third Wave Technologies are developing HPV tests...
Trinity gains bioMerieux blood coagulation testing line
Automated instruments and reagent menu for blood clotting parameter analysis composing bioMerieux's hemostasis product line are acquired by diagnostics firm Trinity Biotech May 25. Trinity will pay up to $51.9 mil., including $40 mil. at closing, with deferred payments of up to $11.9 mil. over two years. Combining the bioMerieux line with Trinity's existing coagulation testing products will add $40 mil. to Trinity's revenue next year and boost its share of the $600 mil. worldwide coagulation testing market from its current 5% level to an estimated 13%, the firm says. The market is growing at about 5% annually. The deal is in line with bioMerieux' focus on infectious diseases, cancer and cardiovascular diseases...